Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024

March 5, 2024

WATERTOWN, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”)

May 3, 2024

Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

WATERTOWN, Mass., May 03, 2024 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) Read More

April 24, 2024

Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

WATERTOWN, Mass., April 24, 2024 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) Read More

April 23, 2024

Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

WATERTOWN, Mass., April 23, 2024 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) Read More

Share this article: